Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 3

2(40.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03785106Phase 3Active Not Recruiting

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Role: collaborator

NCT06279507Phase 4Recruiting

Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis

Role: collaborator

NCT03727152Phase 3Completed

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

Role: collaborator

NCT04559165Not ApplicableUnknown

Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore

Role: collaborator

NCT03170687Not ApplicableCompleted

Comparative Outcomes Between Foot Cast and Short Leg Cast in the Patients With Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)

Role: collaborator

NCT01509118Unknown

Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery

Role: collaborator

All 6 trials loaded